

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/173207 A1

(51) International Patent Classification:
C07D 403/04 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2024/015330

(22) International Filing Date:
12 February 2024 (12.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/484,599 13 February 2023 (13.02.2023) US
63/516,673 31 July 2023 (31.07.2023) US

(71) Applicant: MIRATI THERAPEUTICS, INC. [US/US];
3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: ACHMATOWICZ, Michal; 4763 Camini-
to Canor, San Diego, CA 92130 (US). KULYK, Svit-
lana; 11142 Socorro Sstreet, San Diego, CA 92129 (US).
SMITH, Christopher, Ronald; 3316 Windbreak Court,
San Diego, CA 92130 (US). WANG, Nan; J-star Research,
Inc., 3001 Hadley Road, Suites 1-5a, South Plainfield, NJ
07080 (US). SHAH, Harsh; J-star Research, Inc., 3001
Hadely Road, Suites 1-5a, South Plainfield, NJ 07080 (US).
XIE, Tian; J-star Research, Inc., 3001 Hadely Road, Suites
1-5a, South Plainfield, NJ 07080 (US). GAO, Qi; J-star Re-
search, Inc., 3001 Hadely Road, Suites 1-5a, South Plain-
field, NJ 07080 (US).

(74) Agent: SARUSSI, Steven, J.; McDonnell Boehnen Hul-
bert & Berghoff LLP, 300 South Wacker Drive, Chicago, IL
60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

WO 2024/173207 A1

(54) Title: CRYSTALLINE FORMS OF 2-(4-(4-(AMINOMETHYL)-L-OXO-L,2-DIHYDROPHthalAZIN-6-YL)-L-METHYL-LH-PYRAZOL-5-YL)-4-CHLORO-6- CYCLOPROPOXY-3-FLUOROBENZONITRILE

(57) Abstract: Disclosed herein are crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3- fluorobenzonitrile free base, pharmaceutically acceptable compositions comprising these crystalline forms, and methods for using these crystalline forms.